Companies · Biotechnology

Cernostics, Inc.

PITTSBURGH · Biotechnology

Diligence memoA one-page analyst read on Cernostics, Inc. — recommendation, valuation, rhythm, risks.
$16.3M
Total raised · real
8
Rounds
2.4×
Latest step-up
Top 36%
Sector rank · raised
Series A
Latest stage · inferred · Thu Jul 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Cernostics, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.73× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
  • Within the normal band (73% of peer median) for its niche.
Dormant
  • Last raise 5.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Cernostics, Inc. is one of 4293 Biotechnology companies tracked from PITTSBURGH. By capital raised it ranks mid-pack (ahead of 65% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2021-07-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2009-09-30 Raised $394K (real) Modeled valuation $22M (est)Pre-Seed2009Pre-Seed · 2009-09-30 Raised $394K (real) Modeled valuation $22M (est)Pre-Seed2009Seed · 2010-05-25 Raised $2.6M (real) Modeled valuation $116M (est)Seed2010Seed · 2010-05-25 Raised $2.6M (real) Modeled valuation $116M (est)Seed2010Seed · 2012-07-30 Raised $125K (real) Modeled valuation $5.6M (est)Seed2012Seed · 2013-07-18 Raised $1.4M (real) Modeled valuation $63M (est)Seed2013Seed · 2015-05-27 Raised $2.0M (real) Modeled valuation $87M (est)Seed2015Seed · 2016-08-16 Raised $1.3M (real) Modeled valuation $58M (est)Seed2016Seed · 2018-03-15 Raised $2.5M (real) Modeled valuation $111M (est)Seed2018Series A · 2021-07-15 Raised $6.0M (real) Modeled valuation $131M (est)Series A2021+$394K+$2.6M+$2.6M+$125K+$1.4M+$2.0M+$1.3M+$2.5M+$6.0MCumulative $19M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$394K · 2009
Pre-Seed extension$394K · 2009
Seed$2.6M · 2010
Seed extension$2.6M · 2010
Seed extension$125K · 2012
Seed extension$1.4M · 2013
Seed extension$2.0M · 2015
Seed extension$1.3M · 2016
Seed extension$2.5M · 2018
Series A$6.0M · 2021

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$131.2M
Base estimate est.
$6.5M
Conservative case
$561.6M
Upside case
$27.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $21.7M · 2009-09-302009Pre-Seed · modeled $21.7M · 2009-09-30Seed · modeled $116.3M · 2010-05-25Seed · modeled $116.3M · 2010-05-25Seed · modeled $5.6M · 2012-07-30Seed · modeled $63.2M · 2013-07-18Seed · modeled $87.1M · 2015-05-27Seed · modeled $57.7M · 2016-08-16Seed · modeled $111.0M · 2018-03-15Series A · modeled $131.2M · 2021-07-152021
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
5.0 yr
Elapsed time used
5.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$1.4M/yr
Capital velocity
16.8 yr
On record since
2009
First round
10
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.3× above median
This company$16.3M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.1× above median
This company$6.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.0× above median
This company$131.2M
Sector median$64.2M

Raised more than 65% of sector peers (real $). Modeled value above 63% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #143 of 216.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $485.3M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)Cernostics, Inc. (this company) Raised $16.3M · modeled $131.2M (est)Cernostics, Inc.
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Taiga Biotechnologies, Inc.Series A$37.9M$485.3M2.68×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
Cernostics, Inc. this companySeries A$16.3M$131.2M0.73×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$394K2009-09-30$2.2M$21.7M85%
Pre-Seed$394K2009-09-30$2.2M$21.7M85%
Seed$2.6M2010-05-25$13.1M$116.3M85%
Seed$2.6M2010-05-25$13.1M$116.3M85%
Seed$125K2012-07-30$625K$5.6M85%
Seed$1.4M2013-07-18$7.1M$63.2M85%
Seed$2.0M2015-05-27$9.8M$87.1M85%
Seed$1.3M2016-08-16$6.5M$57.7M85%
Seed$2.5M2018-03-15$12.5M$111.0M90%
Series A$6.0M2021-07-15$27.2M$131.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$394K2009-09-30
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$394K2009-09-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  3. Seed$2.6M2010-05-25
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 6.7× larger than the prior — scaling up.
    • 5 investors on this round.
  4. Seed$2.6M2010-05-25
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 5 investors on this round.
  5. Seed$125K2012-07-30
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 21.0× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  6. Seed$1.4M2013-07-18
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 11.4× larger than the prior — scaling up.
    • 3 investors on this round.
  7. Seed$2.0M2015-05-27
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 7 investors on this round.
  8. Seed$1.3M2016-08-16
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  9. Seed$2.5M2018-03-15
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • 1 investor on this round.
  10. Series A$6.0M2021-07-15
    • Raised again after 40 mo — slower than the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
    • 4 investors on this round.
Intelligence
2022 ~Q4
Modeled next raise · ~16mo cadence
$14.3M
Modeled next size est.range $9.3M$22.9M
2.4×
Last step-up
$1.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Paul Schmitt4 other2015-05
D. Lansing Taylor3 other2009-09
Paul Touhey2 other2012-07
Dean Miller1 other2012-07
Steve Grenfell1 other2015-05
Courtland Longest2018-03
Dean Lansing Miller2009-09
Franklyn Lansing Prendergast2009-09
Gregg J. Fergus2021-07
Jack Lansing Reynolds2009-09
James Lansing Datin2009-09
James Peters2015-05
Jim Peters2013-07
LeRoy Lansing Metz2009-09
LeRoy Metz2016-08
Matthew Lansing Malenfant2009-09
Michael Hoerres2012-07
Michael J. Hoerres2021-07
Michel Lansing Nederlof2009-09
Noel Doheny2013-07
Noel J. Doheny2021-07
Prince Denise2012-07
Rosemary Lansing Mazanet2009-09
Steve Lansing Grenfell2010-05
Registry & provenance

Cernostics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1474724
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Dermata Therapeutics, LLCBiotechnologySeries A$16.2M$106.3Msame sector · same stage
Asterias Biotherapeutics, Inc.BiotechnologySeries A$16.6M$144.6Msame sector · same stage
Medical 21, Inc.BiotechnologySeries A$16.7M$102.9Msame sector · same stage
Mabvax Therapeutics IncBiotechnologySeries A$15.6M$109.9Msame sector · same stage
InflammX Therapeutics, Inc.BiotechnologySeries A$15.4M$156.4Msame sector · same stage
Novoron Bioscience, Inc.BiotechnologySeries A$15.2M$135.4Msame sector · same stage
Dimension Inx Corp.BiotechnologySeries A$17.7M$126.1Msame sector · same stage
eXIthera Pharmaceuticals, Inc.BiotechnologySeries A$15.0M$108.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Cerium Pharmaceuticals, Inc.BiotechnologySeries A$193.4M89%
Celsense IncBiotechnologyPre-Seed$27.6M87%
Cerecin Inc.BiotechnologySeries C$34.1M86%
Celcuity Inc.BiotechnologySeries D+$691.9M86%
CeraRoot USA IncBiotechnologyPre-Seed$1.6M85%
Celularity Inc.BiotechnologySeries C$3.2B85%
Ceretype Neuromedicine, Inc.BiotechnologySeed$1.8M85%
Cereius, Inc.BiotechnologySeed$44.4M85%
Frequently asked
How much funding has Cernostics, Inc. raised?
Cernostics, Inc. has raised approximately $16.3M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is Cernostics, Inc.'s estimated valuation?
Provath's modeled valuation for Cernostics, Inc. is approximately $131.2M (modeled range $6.5M–$561.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cernostics, Inc. at?
Cernostics, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Jul 15.
What does Cernostics, Inc. do and where is it based?
Cernostics, Inc. operates in the Biotechnology sector, based in PITTSBURGH.
Explore related

See where Cernostics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cernostics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.